Silence Therapeutics plc
SLNCF
$4.00
-$1.50-27.27%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.23% | -4.91% | -95.57% | 14.04% | -58.30% |
| Total Depreciation and Amortization | -16.29% | -9.67% | -6.41% | -1.99% | -4.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.65% | -3.33% | 54.74% | -70.13% | 76.27% |
| Change in Net Operating Assets | 151.69% | 75.52% | 130.76% | -279.99% | -907.02% |
| Cash from Operations | 51.52% | 7.40% | 7.94% | -32.69% | -147.85% |
| Capital Expenditure | 98.31% | 76.28% | 73.93% | 21.48% | -61.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 509.98% | 139.69% | -120.35% | 180.36% | 28.51% |
| Cash from Investing | 505.90% | 138.86% | -118.48% | 180.09% | 28.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.97% | -99.99% | -99.99% | -99.99% | -94.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.97% | -99.99% | -99.99% | -100.05% | -95.13% |
| Foreign Exchange rate Adjustments | -158.44% | -116.51% | 225.00% | -76.99% | -74.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.35% | 23.91% | -309.46% | -107.87% | -193.06% |